Trial · NCT07538271
A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer
NCT07538271, Phase 2, Not yet recruiting, Yayi He
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer. Trials, record NCT07538271. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07538271
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer
- NCT number
- NCT07538271
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 33 participants, estimated
- Lead sponsor
- Yayi He
- Conditions
- SCLC, Extensive Stage
- Interventions
- benmelstobart, Anlotinib, Carboplatin or cisplatin, Etoposide, Thoracic Radiotherapy
- First posted
- 2026-04-20
- Last updated
- 2026-04-20
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | Baseline at screening, after every 2 treatment cycles (each cycle is 21 days), end of treatment, up to disease progression, assessed up to approximately 24 months | Investigator-assessed ORR per RECIST 1.1 in ES-SCLC patients treated with benmelstobart plus anlotinib and chemotherapy followed by thoracic radiotherapy. |
| Secondary | Progression-Free Survival (PFS) | Date of first study treatment to date of disease progression or death from any cause, last follow-up, assessed up to approximately 24 months | Time from first treatment to disease progression or death from any cause, whichever occurs first |
| Secondary | Overall Survival (OS) | From date of first study treatment to date of death from any cause or last follow-up, whichever occurs first, assessed up to approximately 24 months | Time from first study treatment to death from any cause; censored at last follow-up for alive subjects |
| Secondary | 6-Month Progression-Free Survival Rate | 6-month time point after first treatment, follow-up cutoff | Estimated proportion of subjects without progression and alive at 6 months after first treatment using Kaplan-Meier method |
| Secondary | Serious Adverse Event (SAE) | from date of first study drug administration , follow-up until resolution or stabilization, assessed up to approximately 24 months | Collect SAEs resulting in death, life-threatening condition, hospitalization, disability per CTCAE 5.0 and ICH-GCP, document and report |
| Secondary | Adverse Event (AE) | From signing informed consent through study completion and safety follow-up, assessed up to approximately 24 months | Record all new or worsening unfavorable medical events, grade and calculate incidence according to CTCAE 5.0 |
| Secondary | 18-Month Overall Survival Rate | 18-month time point after first treatment, follow-up cutoff | Estimated proportion of alive subjects at 18 months after first treatment via Kaplan-Meier method |
| Secondary | Duration of Response (DOR) | From date of first confirmed objective response (CR/PR) until date of disease progression, death from any cause, or initiation of new antitumor therapy, whichever occurs first, assessed up to approximately 24 months | Time from first confirmed CR/PR to disease progression, death from any cause, or initiation of new antitumor therapy |
| Secondary | 12-Month Progression-Free Survival Rate | 12-month time point after first treatment, follow-up cutoff | Estimated proportion of progression-free and alive subjects at 12 months via Kaplan-Meier method |
| Secondary | 12-Month Overall Survival Rate | 12-month time point after first treatment, follow-up cutoff | Estimated proportion of alive subjects at 12 months after first treatment using Kaplan-Meier method |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07538271
GET https://conductscience.org/api/trials/v1/NCT07538271/registered